Novartis Boosts Cancer Immunotherapy Research Efforts

Novartis is accelerating its efforts in the field of cancer immunotherapy with the launch of a dedicated research group and an alliance with US-based Aduro Biotech. The multi-year collaboration is focused on developing novel immunotherapies derived from Aduro's cyclic dinucleotide (CDN) approach to target the STING (stimulator of interferon genes) receptor that, when activated, can initiate tumor-specific immune responses.

Novartis will make an upfront payment of $200 million to Aduro which, if all development milestones are met, could receive additional payments of up to $500 million. Novartis has also made an initial investment of $25 million for a 2.7% equity stake in Aduro and has committed to invest another $25 million at a future date. Aduro will lead commercialisation efforts and sales in the US, while Novartis will lead activities in the rest of the world.

Meanwhile, the research and development group will be headed by cancer vaccine expert Glenn Dranoff who has joined Novartis from the Dana Farber Cancer Institute.

Mark Fishman, president of the Novartis Institutes for BioMedical Research, said: "Immunotherapy is one of the exciting frontiers in oncology today. STING agonists have the potential to fully activate the immune system to attack a broader range of tumors. Under Glenn Dranoff's leadership, our new immune-oncology research group will aggressively drive our current programs to the clinic and explore new directions for both mono and combination therapies."

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.